Bristol-Myers Squibb Company

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Bristol Myers is Cheaper Than Pfizer, but Its 40% Earnings Jump Has a ...

Earnings report Guidance raised AI-generated analysis

πŸ“ˆ Bristol-Myers Squibb reported a 40% rise in second-quarter adjusted earnings per share to $2.04, driven by a 6% increase in total revenue to $13.0 billion.

πŸ’Š The company's Growth Portfolio grew 15% to $7.6 billion, now representing approximately 58% of quarterly revenue with strong performance from Reblozyl, Breyanzi, and Camzyos.

πŸ“ˆ Management raised its annual revenue guidance to $49–$50 billion and adjusted EPS guidance to $6.75–$7.00, signaling confidence in the non-COVID pipeline.

⚠️ The reported earnings growth is partially offset by a legacy portfolio decline of 4% to $5.42 billion, with Revlimid dropping 49% and Pomalyst/Imnovid falling 71%.

πŸ” Adjusting for a one-time $0.57-per-share R&D charge from the prior quarter reveals that underlying comparable earnings were effectively flat at approximately $2.03 per share.

πŸ’° Bristol-Myers Squibb trades at a forward multiple of 9.36x earnings, appearing slightly cheaper than Pfizer's 9.67x despite stronger recent revenue growth.

πŸ“Š The company successfully diversified its revenue base, reducing reliance on any single blockbuster drug through the expansion of its Growth Portfolio.

Bullish Signals
  • Bristol-Myers Squibb reported a 40% increase in second-quarter adjusted earnings per share to $2.04, driven by strong growth in its diversified Growth Portfolio.
  • The company's Growth Portfolio grew 15% to $7.6 billion, now accounting for roughly 58% of quarterly revenue with significant gains in Reblozyl (29%), Breyanzi (41%), and Camzyos (60%).
  • Management raised its annual revenue outlook to $49–$50 billion and adjusted EPS guidance to $6.75–$7.00, indicating a successful transition away from legacy products.
  • The stock trades at a forward multiple of 9.36x earnings, presenting a potentially attractive valuation relative to peers like Pfizer.
Risk Factors
  • The reported 40% earnings jump is partially an accounting artifact; removing a one-time $0.57-per-share R&D charge from the prior quarter shows underlying comparable earnings were flat at roughly $2.03 per share.
  • The legacy portfolio declined 4% to $5.42 billion, with major declines in Revlimid (down 49%) and Pomalyst/Imnovid (down 71%), creating pressure on overall revenue growth.
  • Despite strong Growth Portfolio performance, the company must continue to replace substantial lost sales from aging medicines to sustain long-term earnings acceleration.
Full Analysis
Bristol-Myers Squibb (NYSE:BMY) reported a 40% increase in second-quarter adjusted earnings per share, rising from $1.46 to $2.04, driven by strong growth in its Growth Portfolio which now accounts for roughly 58% of quarterly revenue at $7.6 billion. Key drivers included significant gains in Reblozyl (up 29%), Breyanzi (up 41%), and Camzyos (up 60%). Management raised its annual revenue outlook to between $49 billion and $50 billion, and adjusted EPS guidance to a range of $6.75 to $7.00. However, the reported earnings jump is partially obscured by accounting adjustments; removing a one-time net acquisition-related R&D charge from the prior quarter reveals that underlying comparable earnings were approximately flat at roughly $2.03 per share. Despite this, BMY's legacy portfolio continues to face headwinds with overall revenue falling 4% to $5.42 billion, led by steep declines in Revlimid (down 49%) and Pomalyst/Imnovid (down 71%). The company trades at a forward multiple of about 9.36x earnings. In a comparative analysis with Pfizer, BMY appears cheaper on an earnings basis despite showing stronger recent revenue growth than its competitor. While Pfizer also demonstrated operational growth in non-COVID products like Padcev and Lorbrena, it faces the challenge of offsetting declining COVID-related sales against rising non-vaccine revenue. The article concludes that neither company's headline EPS fully captures the complexities of their ongoing product transitions and portfolio shifts.